Cancer Family
Epithelial Neoplasm
CI-CAN-00000016Explore in graph →
Non-malignant7,531 active trials118 approved drugs1,152 evidence items
- NCIt
- C3709
Loading cancer entity…
Cancer Family
CI-CAN-00000016Explore in graph →
Clinical trials
26,887 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04965454 | Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma(ExTRACT-HCC) | recruiting | Phase 2 | 80 | Queen's Medical CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05099172 | First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) | recruiting | Phase 1 / Phase 2 | 400 | BayerINDUSTRY | 16 |
| Aug 12, 2026 |
| clinicaltrials |
| NCT05544136 | A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer | recruiting | Phase 2 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06525766 | Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer | recruiting | Phase 2 | 35 | Mayo ClinicOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06543576 | External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer | recruiting | Phase 1 / Phase 2 | 35 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07155200 | Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) | recruiting | Phase 1 / Phase 2 | 42 | Washington University School of MedicineOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07260175 | Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma(adIVO) | recruiting | Phase 2 | 40 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07324629 | Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma | recruiting | Phase 2 | 30 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07697586 | SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer | recruiting | Phase 2 | 206 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07759856 | NK Cells Plus ICI for SCLC Maintenance(NK-ICI-SCLC) | recruiting | Phase 2 | 42 | Tianjin First Central HospitalOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04939051 | Obeticholic Acid for Prevention in Barrett's Esophagus | recruiting | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05592626 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors(START-001) | recruiting | Phase 1 / Phase 2 | 366 | Marengo Therapeutics, Inc.INDUSTRY | 4 | Aug 11, 2026 | clinicaltrials |
| NCT05706129 | A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 270 | Lumara Bio Oncologics GmbHINDUSTRY | 2 | Aug 11, 2026 | clinicaltrials |
| NCT06236139 | Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 48 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06656598 | Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer(SPORADIC) | recruiting | Phase 2 | 152 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06880523 | STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma(SLIDE-HCC) | recruiting | Phase 2 | 140 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06904183 | Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT | recruiting | Phase 2 | 320 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07239596 | Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom | recruiting | Phase 1 / Phase 2 | 92 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07615348 | CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk(PERFUMER-70) | recruiting | Phase 2 | 75 | Jinling Hospital, ChinaOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05518903 | Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma | recruiting | Phase 2 | 130 | Mayo ClinicOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05674396 | 3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial | recruiting | Phase 2 | 108 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05832086 | Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes | recruiting | Phase 2 | 138 | Stephen FreedlandOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06222489 | Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT | recruiting | Phase 2 | 16 | The Netherlands Cancer InstituteOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06576115 | Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer | recruiting | Phase 2 | 30 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07044310 | 5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss | recruiting | Phase 2 | 38 | Mayo ClinicOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07098988 | Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC | recruiting | Phase 2 | 107 | CatalYm GmbHINDUSTRY | 7 | Aug 10, 2026 | clinicaltrials |
| NCT07590531 | AMT-116 in Combination With AK112 in Patients With Lung Cancer | recruiting | Phase 1 / Phase 2 | 118 | Multitude Therapeutics Inc.INDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07755449 | CLEAR (Cervical Lymphatic Exclusion in Adjuvant Radiation)(CLEAR) | recruiting | Phase 2 | 101 | Institut Català d'OncologiaOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT04752722 | LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | recruiting | Phase 1 / Phase 2 | 350 | enGene, Inc.INDUSTRY | 10 | Aug 7, 2026 | clinicaltrials |
| NCT06515990 | A Study of DM005 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 208 | Doma Biopharmaceutical(Suzhou)Co., Ltd.INDUSTRY | 2 | Aug 7, 2026 | clinicaltrials |
| NCT06751329 | A Study of DM002 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 280 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd.INDUSTRY | 2 | Aug 7, 2026 | clinicaltrials |
| NCT07751055 | Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer(NEOCRTE2601) | recruiting | Phase 2 | 51 | Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06145633 | Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 2 | 15 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06176261 | DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs | recruiting | Phase 2 | 58 | Nancy Lin, MDOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06188520 | A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors(CYCAD-1) | recruiting | Phase 1 / Phase 2 | 564 | AstraZenecaINDUSTRY | 5 | Aug 6, 2026 | clinicaltrials |
| NCT06417190 | Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology | recruiting | Phase 2 | 20 | Leslie BallasOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06439693 | The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer | recruiting | Phase 2 | 72 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06627270 | Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer | recruiting | Phase 2 | 30 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06634056 | Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation(P4-PACIFIC) | recruiting | Phase 2 | 150 | University Health Network, TorontoOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06891560 | A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma | recruiting | Phase 2 | 34 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07043270 | 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC | recruiting | Phase 2 | 35 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07455903 | Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT | recruiting | Phase 2 | 50 | Baptist Health South FloridaOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04900623 | Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study | recruiting | Phase 2 | 145 | Jonathan Schoenfeld, MD, MPHOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05318469 | Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 34 | Yuan YuanOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06445114 | Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer | recruiting | Phase 2 | 50 | Zachary ZumstegOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06449313 | Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features(NEO-SURG) | recruiting | Phase 2 | 21 | Georgetown UniversityOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06706076 | A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations(SOLARA) | recruiting | Phase 1 / Phase 2 | 675 | BlossomHill TherapeuticsINDUSTRY | 9 | Aug 5, 2026 | clinicaltrials |
| NCT06809140 | Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer | recruiting | Phase 2 | 75 | Matthew GalskyOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07111520 | A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) | recruiting | Phase 1 / Phase 2 | 880 | BioNTech SEINDUSTRY | 10 | Aug 5, 2026 | clinicaltrials |
| NCT07226544 | Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer | recruiting | Phase 2 | 31 | City of Hope Medical CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 12, 2026source: clinicaltrials